Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Expertise in Hypertriglyceridemia: HELP
J. Sierra-Johnson
Based on 1 article published since 2008
||||
Expertise Level

  What is this?

Expertscape's algorithms degrade at low publication numbers. Thus, with only 1 published article on Hypertriglyceridemia from 2008 through 2019, it is not possible for Expertscape to reliably rate J. Sierra-Johnson's expertise on this topic.

Uncounted papers?
Work Locations
Details
Most likely:    Amgen      
2016
  • Amgen Inc., Thousand Oaks, CA, USA. · Amgen Ltd, Cambridge, UK. · Amgen Inc., Seattle, WA, USA. · Center for Metabolic Research, Veterans Administration San Diego Healthcare System, San Diego, CA, USA. · University of Texas Southwestern Medical Center, Dallas, TX, USA. · Pubmed 26434934
Specific Interests

In the titles of their published articles, experts often reveal their very specific interests.

Here is the title of the one article written by J. Sierra-Johnson in 2008-2019 about Hypertriglyceridemia:

  • AMG 151 (ARRY-403), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes. 2016
Show Full Article Record
Google Searches

Learn more about J. Sierra-Johnson using the ready-made Google searches below.
This is essential! -- Publications never tell the whole story!

General Search:
Amgen
Affiliation Timeline
Click for institutional directory in table below. (Not always available.)
What is this?
Amgen
2016
  • Amgen Inc., Thousand Oaks, CA, USA. · Amgen Ltd, Cambridge, UK. · Amgen Inc., Seattle, WA, USA. · Center for Metabolic Research, Veterans Administration San Diego Healthcare System, San Diego, CA, USA. · University of Texas Southwestern Medical Center, Dallas, TX, USA. · Pubmed 26434934
Yearly article counts 000100000000
Remember this Person You can save this page -- like a bookmark -- so it's remembered for you on the Expertscape "Saved Pages" page, which is always easily available from the page-top menu bar throughout the site.